Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib as First Line Therapy for Metastatic HR-deficient Pancreatic Cancer
NCT05442749Phase 2Terminated
- Sponsor
- Centre Léon Bérard
- Start
- Oct 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of niraparib in pancreatic cancer (PC), sponsored by Centre Léon Bérard. Started Oct 2022; status: terminated.
02
Drugs
niraparib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05442749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05442749.